TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31397597

Group type: EXPERIMENTAL
Intervention: naproxen sodium (440 mg)
Number of subjects: 189
Study: 28931943

Group type: EXPERIMENTAL
Intervention: Paired Vagus Nerve Stimulation (VNS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Paired VNS
Number of subjects: 30
Study: 26114906

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 48
Study: 24019420

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100000 IU, 6 quarterly doses)
Number of subjects: 3046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 3046
Study: 22288155

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (600 mg once a day, i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg once a day, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19336459

Group type: EXPERIMENTAL
Intervention: Epidural motor cortex stimulation (MCS) 'on'
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epidural motor cortex stimulation (MCS) 'on' during open phase
Number of subjects: 16

Group type: COMPARATOR
Intervention: Epidural motor cortex stimulation (MCS) 'off'
Number of subjects: 16
Study: 16928841

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study: 15288411

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 150-225 mg
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 11565622

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 108
Study: 9629818

Group type: EXPERIMENTAL
Intervention: Non-prosecutory enforcement of public health legislation (intervention)
Number of subjects: 12502

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12502
Study: 8162464

Group type: EXPERIMENTAL
Intervention: Tenoxicam for 14 days
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 73
Study: 3466563

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole plus colistin
Number of subjects: 56
Study: 31032881

Group type: EXPERIMENTAL
Intervention: Simulated stopping of trials before reaching planned sample size
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group from RCTs (not specified)
Number of subjects: 0
Study: 28689453

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF (elvitegravir, cobicistat, emtricitabine, and tenofovir DF)
Number of subjects: 433

Group type: COMPARATOR
Intervention: NNRTI + FTC/TDF (no-switch)
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF
Number of subjects: 433
Study: 26537218

Group type: EXPERIMENTAL
Intervention: High PL krill oil (3 g/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low PL krill oil (1.5 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 20
Study: 23337231

Group type: EXPERIMENTAL
Intervention: Resource Use Log (RUL)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No Resource Use Log (Control)
Number of subjects: 85
Study: 21168198

Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/m2 daily for 5 days every 21 days (regimen I)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Topotecan 4.0 mg/m2/day on days 1, 8, and 15 of a 28-day cycle (regimen II)
Number of subjects: 81
Study: 19675193

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 83
Study: 17348888

Group type: EXPERIMENTAL
Intervention: Single-tooth implants
Number of subjects: 62

Group type: COMPARATOR
Intervention: Natural tooth
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intraindividual comparison (implant vs natural tooth)
Number of subjects: 62
Study: 14977817

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Gefitinib 500 mg/day
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both doses of gefitinib combined
Number of subjects: 216

Group type: COMPARATOR
Intervention: Gefitinib (250 or 500 mg daily)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 216
Study: 11673773

Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (35% of energy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Low-fat diet (20% of energy)
Number of subjects: 101
Study: 9134944

Group type: EXPERIMENTAL
Intervention: 200 mg/d of vitamin E
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 60 mg/d of vitamin E
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 800 mg/d of vitamin E
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 88
Study: 7631080

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reoperation
Number of subjects: 27
Study: 2979270

Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg o.m.)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Cimetidine (400 mg b.d.)
Number of subjects: 152
Study: 28846200

Group type: EXPERIMENTAL
Intervention: Lung Flute (LF)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hypertonic saline inhalation (HSI)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No induction
Number of subjects: 64
Study: 26954966

Group type: EXPERIMENTAL
Intervention: Stroke care pathway (CP)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional care (CC)
Number of subjects: 162
Study: 23456902

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (motivational materials and small-group instruction)
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1196
Study: 23297638

Group type: EXPERIMENTAL
Intervention: Antibiotics of a wide spectrum of action
Number of subjects: 110
Study: 20545993

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg per day for 3 months)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg per day for 3 months)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 92
Study: 18677234

Group type: EXPERIMENTAL
Intervention: Group A (GrA): 15 min WC application without reheating
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group B (GrB): 30 min WC application with reheating every 2 min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group C (GrC): 30 min WC application optimizing contact with the lower lid and reheating every 2 min
Number of subjects: 32
Study: 15856233

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m(2) followed by Carboplatin AUC 7
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Docetaxel 70 mg/m(2) followed by Carboplatin AUC 6
Number of subjects: 46
Study: 12067917

Group type: EXPERIMENTAL
Intervention: 400 microg/kg FFR‐rFVIIa and 40 to 50 U/kg heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 microg/kg FFR‐rFVIIa and 100 U/kg heparin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 microg/kg FFR‐rFVIIa and 100 U/kg heparin
Number of subjects: 24
Study: 10588300

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 2022
Study: 8724292

Group type: EXPERIMENTAL
Intervention: pANCA+ patients
Number of subjects: 385

Group type: COMPARATOR
Intervention: pANCA- patients
Number of subjects: 385
Study: 1549928

Group type: EXPERIMENTAL
Intervention: Lidocaine spray 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 4040338

Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myringotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adenoidectomy and myringotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of adenoidectomy and tympanostomy tubes
Number of subjects: 0
Study: 31464525

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 0
Study: 29679586

Group type: EXPERIMENTAL
Intervention: Video Laryngoscope (VL)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Macintosh Laryngoscope (ML)
Number of subjects: 78
Study: 24666696

Group type: EXPERIMENTAL
Intervention: SB‐705498 (600 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23082701

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 138
Study: 20453006

Group type: EXPERIMENTAL
Intervention: Functional regulator III (FR‐3) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (Class I malocclusion)
Number of subjects: 15
Study: 17336790

Group type: EXPERIMENTAL
Intervention: 8-week psychoeducational intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Self-monitoring control (SMC) group
Number of subjects: 24
Study: 16340712

Group type: EXPERIMENTAL
Intervention: Education regarding back therapy and pain management combined with three consecutive days of topical heat therapy (104 degrees F or 40 degrees C for 8 hours)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Education regarding back therapy and pain management alone
Number of subjects: 43
Study: 12081835

Group type: EXPERIMENTAL
Intervention: Iron supplements (1 mg x kg(‐1) x d(‐1)) from 4 to 9 mo of age
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Placebo from 4 to 6 mo and iron supplements from 6 to 9 mo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo from 4 to 9 mo
Number of subjects: 25
Study: 9873848

Group type: EXPERIMENTAL
Intervention: HIV protease inhibitors
Number of subjects: 19
Study: 8021437

Group type: EXPERIMENTAL
Intervention: Citalopram 10-30 mg
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Citalopram 20-60 mg
Number of subjects: 472

Group type: COMPARATOR
Intervention: Imipramine 50-150 mg
Number of subjects: 472
Study: 2563985

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 31805822

Group type: EXPERIMENTAL
Intervention: Method of adjustment
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Two-alternative forced-choice (2AFC) method
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Likeness rating (LR)
Number of subjects: 59
Study: 28782109

Group type: EXPERIMENTAL
Intervention: RBC transfusion triggered by hb < 8 g/dl
Number of subjects: 58

Group type: COMPARATOR
Intervention: RBC transfusion triggered by hb < 9.7 g/dl
Number of subjects: 58
Study: 24141892

Group type: EXPERIMENTAL
Intervention: Group ≥18 years (n = 40)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Group <18 years (n = 9)
Number of subjects: 49
Study: 23238884

Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) technique
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 65
Study: 21572152

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg, 80 mg, or 120 mg daily
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Febuxostat (any dose)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 17925336

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg every day)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 17183893

Group type: EXPERIMENTAL
Intervention: Interventional trials from 1974-1978
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials from 1974-1978
Number of subjects: 821

Group type: COMPARATOR
Intervention: Animal/laboratory articles
Number of subjects: 821

Group type: COMPARATOR
Intervention: Review articles
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Descriptive trials
Number of subjects: 821

Group type: COMPARATOR
Intervention: Uncontrolled clinical trials
Number of subjects: 821

Group type: COMPARATOR
Intervention: Non-randomized controlled trials
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: All interventional trials criteria
Number of subjects: 821
Study: 14680343

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 42448

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 42448

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 42448

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 42448

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 42448

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 42448
Study: 10750626

Group type: EXPERIMENTAL
Intervention: Exercise and diet (ED)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 91
Study: 8881623

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tracheal intubation (ET)
Number of subjects: 20
Study: 8097102

Group type: EXPERIMENTAL
Intervention: ebastine (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: diazepam (15 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 3746897

Group type: EXPERIMENTAL
Intervention: Psychological group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Biological cause group
Number of subjects: 51

Group type: COMPARATOR
Intervention: No information group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 51
Study: 29559597

Group type: EXPERIMENTAL
Intervention: Ozonated water bath and ozonated oil topical application once a day for 4 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Naftifine hydrochloride and ketoconazole cream once a day for 4 weeks
Number of subjects: 60
Study: 26927237

Group type: EXPERIMENTAL
Intervention: Weekly use of ibuprofen
Number of subjects: 11795

Group type: COMPARATOR
Intervention: Puberty onset after 15 years of age
Number of subjects: 11795

Group type: COMPARATOR
Intervention: Vitamin use
Number of subjects: 11795
Study: 24631057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ondansetron 2 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 128
Study: 22588047

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR; containing ∼5.0 mmol of nitrate)
Number of subjects: 12
Study: 20179901

Group type: EXPERIMENTAL
Intervention: Intensive supervised pelvic floor muscle training (PFMT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Unsupervised pelvic floor muscle training (PFMT)
Number of subjects: 62
Study: 18391640

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Strength Training + Aerobic Exercise (ST+AE)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Stretching Exercises (Control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Plasma vasoconstrictor hormones
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Carotid artery vasoreactivity
Number of subjects: 37
Study: 15798044

Group type: EXPERIMENTAL
Intervention: Treatment to lower intraocular pressure
Number of subjects: 2

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2
Study: 12213354

Group type: EXPERIMENTAL
Intervention: Sarpogrelate hydrochloride (5‐HT(A2) receptor antagonist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 10
Study: 10626097

Group type: EXPERIMENTAL
Intervention: levodopa-benserazide dispersible formulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: standard form
Number of subjects: 8
Study: 7854533

Group type: EXPERIMENTAL
Intervention: Autistic patients
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal healthy volunteers
Number of subjects: 56
Study: 1659253

Group type: EXPERIMENTAL
Intervention: Esmolol (1.0 mg/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 micrograms/kg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Labetalol (0.3 mg/kg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 4
Study: 6101843

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 31364872

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study: 28363322

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Oriented Recovery Enhancement (MORE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Support Group (SG)
Number of subjects: 55
Study: 26692178

Group type: EXPERIMENTAL
Intervention: Clinic-wide training intervention on long-acting reversible contraception
Number of subjects: 648

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Public health insurance
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: State Medicaid enrollees abortion coverage
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: State mandates for private health insurance to cover contraception
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Private insurance used to pay for abortion
Number of subjects: 648
Study: 24395492

Group type: EXPERIMENTAL
Intervention: Pain assessment using various pain scales and questionnaires
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Thermal threshold testing for cold and warm detection
Number of subjects: 49
Study: 21541030

Group type: EXPERIMENTAL
Intervention: High-temperature meat diet with inhibitors (cruciferous vegetables, yogurt, chlorophyllin tablets)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High-temperature meat diet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhibitor diet
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-temperature meat diet
Number of subjects: 16
Study: 19010741

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Clonidine (100 microg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17474807

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: CP-448,187 (3 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 15632984

Group type: EXPERIMENTAL
Intervention: Gestalt therapy, Rosen Body Work, and Cranio Sacral therapy (2-day course followed by 6-10 individual sessions and a 1-day follow-up course)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 87
Study: 11911170

Group type: EXPERIMENTAL
Intervention: Telemedicine intensive care system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study: 9522319

Group type: EXPERIMENTAL
Intervention: Continuous transdermal estrogen replacement therapy (50 micrograms 17/beta‐estradiol/day, eight patches/cycle)
Number of subjects: 2459

Group type: EXPERIMENTAL
Intervention: Cyclical transdermal estrogen replacement therapy (50 micrograms 17/beta‐estradiol/day, six patches/cycle, 3 weeks on, 1 week off)
Number of subjects: 2459

Group type: COMPARATOR
Intervention: Both treatments (Continuous and Cyclical)
Number of subjects: 2459
Study: 7957543

Group type: EXPERIMENTAL
Intervention: 10 mg ciclotropium intravenous infusion
Number of subjects: 12
Study: 3108355

Group type: COMPARATOR
Intervention: Sulpiride (1 mg/kg im) + Placebo (2 ml saline iv)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sulpiride (1 mg/kg im)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sulpiride (1 mg/kg im) + TRH (200 micrograms iv)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control standard insulin tolerance test (0.1 U/kg iv)
Number of subjects: 13
Study: 30357823

Group type: EXPERIMENTAL
Intervention: COSF 20 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: CTAB 20 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: COSF 10 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: CTAB 10 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: COSF 20 mg and COSF 10 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: COSF
Number of subjects: 51
Study: 27387994

Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HDER) 60/30 mg
Number of subjects: 5973

Group type: COMPARATOR
Intervention: Warfarin (INR 2.0-3.0)
Number of subjects: 5973
Study: 24706498

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1580
Study: 22859242

Group type: EXPERIMENTAL
Intervention: SkinMedica (SKM) regimen
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Obagi (OMP) regimen
Number of subjects: 35
Study: 20839238

Group type: EXPERIMENTAL
Intervention: Dextromethorphan plus ultra low-dose quinidine (DMq) at 30/10mg (DMq-30)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Dextromethorphan plus ultra low-dose quinidine (DMq) at 20/10mg (DMq-20)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 18053310

Group type: EXPERIMENTAL
Intervention: 300 mg/d of dietary secoisolariciresinol diglucoside (SDG) from flaxseed extract
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 600 mg/d of dietary secoisolariciresinol diglucoside (SDG) from flaxseed extract
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 15746480

Group type: EXPERIMENTAL
Intervention: Valproate (placebo-controlled study)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study: 12723748

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 84192

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 84192

Group type: EXPERIMENTAL
Intervention: Ibuprofen and Paracetamol
Number of subjects: 84192